In The News Posted November 9, 2019 Share Posted November 9, 2019 REDWOOD CITY, Calif., Nov. 9, 2019 /PRNewswire/ -- Bolt Biotherapeutics, Inc., a private biotechnology company focused on using its Immune-Stimulating Antibody Conjugate (ISAC) platform technology to unleash the power of the immune system to treat cancer, today reported new preclinical... View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.